Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

NCT03284385 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03284385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03284385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 29, 2019
Completion date
April 22, 2027
Enrollment
18 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma, locally advanced clear cell renal cell carcinoma, locally advanced malignant solid neoplasm, metastatic malignant solid neoplasm, metastatic renal cell carcinoma, stage iii renal cell cancer ajcc v8, stage iv renal cell cancer ajcc v8